China Sky One Medical, Inc. Achieves Significant Breakthrough In Check For Sudden Cardiac Death SCD Early Investigation Implements
/* 468x60, */
China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical business producing over-the-counter drugs in the People's State of China ("PRC"), nowadays announced that the Test & Development project for the Company's Sudden Cardiac End (SCD) Early Controversy Kit has been appraised by the Heilongjiang Bureau of Science and Technology. The R&D project was undertaken jointly by China Sky One Medical and Harbin Medical University.
The leader of this project is Prof. Baofeng Yang, the Principal of Harbin Medical University, who is besides the Chief Scientist of Chinese Governmental 973 Project and Standing Employer of the China Pharmaceutical Alliance. Prof. Yang has committed a substantial part of his activity to researching SCD and his essential trial has led to indefinite breakthroughs. In 2008, Prof. Yang and his research team found that the concentration of a substance called "MicroRNA-1" in human blood has positive correlation with the adventure of SCD. After detailed clinical studies involving lousy with samples, Prof. Yang concluded that the vitality of MicroRNA-1 in human blood is a beneficial predictor of SCD, and higher concentrations of MicroRNA-1 means a higher probability of SCD. The discovery was published in the Ledger of Nature-Medicine. In delayed 2008, Prof. Yang received the state patent for this discovery.
In codification to commercialize SCD diagnostic technology, Harbin Medical University transferred the patent especially to Harbin Beginning Bio-Engineering Company Limited, the wholly owned subsidiary of China Sky One Medical, in early 2009. The two parties will collaborate in researching a industry method for the SCD Early Inquiry Kit that includes large scale clinical analysis comparisons. Their research has been going smoothly and according to schedule.
The company of specialists from the Heilongjiang Office of Science and Technology concluded that the research was best-selling and reliably conducted. As a result, the Company is permitted to drive the proof and employ development for its Sudden Cardiac Curtains (SCD) Early Subject Kit, which testament be classified as a civic brand-new product under the diagnostic kit category. The appraisal organization famous that the success of the project would represent a denoting breakthrough in preventing and reducing the threat of SCD.
"We are great-hearted because this project represents one of the bare few proprietary technologies in the bio-diagnostic existence that is owned by the Chinese," Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "We expect to adequate the inexperienced product utilize growth within one year. We accept that there is vast market possible for this fashionable product and that revenues could practicable spread over $20 million a year."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Firm engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Wrapped up its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Corporation ("TDR"), Harbin Early Bio- Engineering Convention Limited ("First"), Heilongjiang Tianlong Pharmaceutical, Inc. ("Tianlong") and Peng Lai Jin Chuang Pharmaceutical Association ("Jin Chuang") the Gathering manufactures and distributes over-the-counter pharmaceutical products, which constitute up its extensive revenue source.
Safe Harbor Statement
Certain of the statements made in the press proceeds cause forward-looking statements within the explanation of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the practice of forward- looking nomenclature such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the contrary thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of advanced product development. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a disparateness of factors, including the risks associated with the effect of changing economic conditions in The People's Republic of China, variations in cash flow, reliance on collaborative retail partners and on cutting edge product development, variations in au courant product development, risks associated with speedy technological change, and the credible of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Interchange Comission from age to time.
Source: China Sky One Medical, Inc
/* 468x60, */
Last relative articles:
- Use Of Statins Increases The Risk Of Developing Type 2 Diabetes But Reduces Coronary Events
- Heart Failure Worse When Right Ventricle Goes Bad
- Cooling Inflammation For Healthier Arteries
- Experts Identify Why Women And African Americans Face A Greater Risk Of Dying From Heart Disease Than White Men And What Can Be Done About It
- New Book Helps Pharmacists Play Larger Role In Heart Health
- Novel Screening Technique Identifies New Effects Of Approved Drugs For Cardiovascular Disease
- Compound Shows Promise Against Intractable Heart Failure
- Researchers Find Air Pollution Linked To Progression Of Atherosclerosis
- Heart-Assist Device Helped Ready 16-Year-Old For Successful Surgery
- Seven Signs That May Warn Of A Rare Heart Condition
medical, sky medical, medical inc, medical university, harbin medical, medical company, medical harbin, medical parties, medical expect, medical science